GLY-230 is under clinical development by Glycadia and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect GLY-230’s likelihood of approval (LoA) and phase transition for Diabetic Retinopathy took place on 20 Dec 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their GLY-230 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
GLY-230 is under development for the treatment of diabetic nephropathy,diabetic retinopathy and diabetic neuropathy, diabetic macrovascular disease and Alzheimer's disease The drug candidate is administered through oral route. It is selective glycation inhibitor. It is a new chemical entity (NCE).
Quick View GLY-230 LOA Data
|Highest Development Stage|